Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1

Conditions

Neoplasm Metastasis 3Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × STA 9090 × Clear all
NCT02192541 2018-03-29

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
5 enrolled 15 charts
Sarcoma

Neoplasms, Sarcoma

NCT01183364 2014-09-19

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

Synta Pharmaceuticals Corp.

Phase 1 Completed
27 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡